Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients.

ABSTRACT:

Background

It is unknown if, after controlling for clinicopathologic variables and treatment, racial disparities in colon cancer outcomes persist. Molecular marker analysis in North American patients comparing Asians with other races has not been reported.

Methods

BRAF (V600E) and KRAS mutations were analyzed in node-positive colon cancer patients (n = 3305) treated with FOLFOX-based chemotherapy in an adjuvant trial (Alliance N0147). Race categories included Asian, black, or white. Cox models were used to estimate disease-free survival (DFS) and time to recurrence (TTR). All statistical tests were two-sided.

Results

BRAF mutation frequency in tumors from whites (13.9%) was twice that of tumors from Asians or blacks. KRAS mutation rates were highest in tumors from bla

SUBMITTER: Yoon HH 

PROVIDER: S-EPMC5758035 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature